Value through Innovation27 July 2016

Clinical Study Results

  • BILB 1941 - Healthy
    Clinical Study Number 1201.1
    Study Indication Healthy
    Product BILB 1941
    Generic Name BILB 1941
    Lab Code
    Clinical Phase I
    Study Title

    Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg,20 mg, 60 mg, 120 mg, 200 mg, 300 mg, 600 mg, 1000 mg, 1500 mg,2000 mg, 2400 mg, and 3000 mg BILB 1941 ZW (PEG 400/TRISsolution) in Healthy Male Subjects, in a Randomised Double Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Three-Way Crossover Bioavailability Comparison of 600 mg BILB 1941 ZW in a PEG 400/TRIS solution and 600 mg BILB 1941 ZW tablet and 600 mg BILB 1941 ZW tablet administered with Food.

    Study Document Trial synopsis 1201.1 english
  • BILB 1941 - Hepatitis C, Chronic
    Clinical Study Number 1201.14
    Study Indication Hepatitis C, Chronic
    Product BILB 1941
    Generic Name BILB 1941
    Lab Code
    Clinical Phase Ib
    Study Title

    A multinational randomised, double-blind, placebo controlled study to evaluatethe antiviral pharmacodynamic effect, safety, and pharmacokinetics of escalatingdoses of BILB 1941 ZW oral solution administered Q8H for five days to patientswith chronic hepatitis C genotype 1 virus infection

    Study Document Trial synopsis 1201.14 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.